Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Seniors - 65 +
  • Washington
  • Seattle


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Addiction Treatment Outcome Monitoring Study
    NCT04155385
    Conditions:   Alcohol Use Disorder;   Substance Use Disorders
    Interventions:   Other: Measurement;   Other: Feedback
    Sponsors:   University of Washington;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    Recruiting
  • PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
    NCT04151940
    Conditions:   Metastatic Lung Non-Small Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Procedure: Positron Emission Tomography;   Procedure: Computed Tomography;   Drug: Chemotherapy;   Biological: Immunotherapy;   Radiation: Radiation Therapy
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Quality of Life in IPF - Patient and Physician Perceptions
    NCT04148157
    Condition:   Idiopathic Pulmonary Fibrosis
    Intervention:  
    Sponsors:   University of Washington;   Washington Research Foundation
    Recruiting
  • A Cross-Functional, Population-Representative, Web-Based, Epidemiologic Study to Estimate the Prevalence and Burden of Nocturia Due to Nocturnal Polyuria in the US
    NCT04125186
    Condition:   Nocturnal Polyuria
    Interventions:   Diagnostic Test: Baseline EpiNP survey;   Diagnostic Test: Bladder diary;   Diagnostic Test: Testing of EpiNP baseline survey, bladder diary and a qualitative interview;   Other: No other intervention
    Sponsor:   Ferring Pharmaceuticals
    Recruiting
  • US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia
    NCT04103879
    Conditions:   High Risk Hematological Malignancy;   Cord Blood Transplant
    Intervention:   Biological: ECT-001-CB (UM171-Expanded Cord Blood Transplant)
    Sponsors:   ExCellThera inc.;   Fred Hutchinson Cancer Research Center
    Recruiting
  • Optimizing Pain Control in Transurethral Resection of the Prostate
    NCT04102566
    Conditions:   Pain;   BPH With Urinary Obstruction;   BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
    Interventions:   Drug: Ibuprofen 600 mg;   Behavioral: Education
    Sponsors:   Benaroya Research Institute;   Virginia Mason Hospital/Medical Center
    Recruiting
  • Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial
    NCT04095663
    Condition:   Diverticulitis
    Interventions:   Procedure: Partial Colectomy;   Other: Medical Management
    Sponsors:   University of Washington;   Patient-Centered Outcomes Research Institute
    Recruiting
  • Comparison of Prosthetic Feet for People With Syme's Amputation (XF Symes Study)
    NCT04086641
    Conditions:   Amputation;   Artificial Limb
    Interventions:   Device: Crossover foot;   Device: Energy Storing Foot
    Sponsor:   University of Washington
    Recruiting
  • Mindful Body Awareness With Buprenorphine for Opioid Use Disorder Treatment
    NCT04082637
    Condition:   Opioid-use Disorder
    Intervention:   Behavioral: Mindful Awareness in Body-oriented Therapy
    Sponsors:   University of Washington;   National Center for Complementary and Integrative Health (NCCIH)
    Recruiting
  • eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors
    NCT04081298
    Conditions:   Cancer Survivor;   Malignant Neoplasm
    Interventions:   Behavioral: Health Education;   Other: Physical Activity;   Other: Text Message;   Other: Web Site;   Device: FitBit;   Device: Actigraph;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • tSCI Contrast Enhanced Ultrasound Study
    NCT04056988
    Condition:   Acute Spinal Cord Injury
    Intervention:   Drug: Perflutren Lipid Microsphere
    Sponsor:   University of Washington
    Recruiting
  • Comparison of Transcutaneous and Epidural Spinal Stimulation for Improving Function
    NCT04043715
    Conditions:   Spinal Cord Injuries;   Spinal Cord Diseases;   Central Nervous System Diseases;   Nervous System Diseases;   Trauma, Nervous System;   Wounds and Injuries
    Interventions:   Device: Transcutaneous spinal stimulation;   Device: Epidural spinal stimulation
    Sponsors:   University of Washington;   U.S. National Science Foundation
    Recruiting
  • Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
    NCT04020575
    Condition:   Metastatic Breast Cancer
    Interventions:   Biological: huMNC2-CAR44 CAR T cells;   Biological: huMNC2-CAR44 CAR T cells @ RP2D
    Sponsors:   Minerva Biotechnologies Corporation;   Fred Hutchinson Cancer Research Center
    Recruiting
  • Online Prenatal Trial in Mindfulness Sleep Management
    NCT04016428
    Conditions:   Pregnancy Related;   Insomnia;   Depression
    Interventions:   Behavioral: OPTIMISM;   Behavioral: Sleep Education
    Sponsors:   University of Washington;   National Institute of Nursing Research (NINR)
    Recruiting
  • Validation of Diagnostics to Identify Glucose-6-phosphate Dehydrogenase Activity in the US
    NCT04010695
    Condition:   G6PD Deficiency
    Intervention:   Diagnostic Test: STANDARD G6PD
    Sponsors:   PATH;   Fred Hutchinson Cancer Research Center
    Recruiting
  • Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
    NCT03991884
    Conditions:   Recurrent B Acute Lymphoblastic Leukemia;   Recurrent B Lymphoblastic Lymphoma;   Refractory B Acute Lymphoblastic Leukemia;   Refractory B Lymphoblastic Lymphoma
    Interventions:   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine;   Drug: Vincristine Sulfate;   Drug: Prednisone;   Drug: Cyclophosphamide;   Biological: Inotuzumab Ozogamicin
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Best Management of Muscle Relaxation- Objective Monitoring
    NCT03958201
    Condition:   Residual Paralysis, Post Anesthesia
    Intervention:   Drug: Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex
    Sponsor:   University of Washington
    Recruiting
  • Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
    NCT03907527
    Conditions:   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Progressive Disease;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma;   Stage III Fallopian Tube Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Primary Peritoneal Cancer AJCC v8;   Stage IIIA Fallopian Tube Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Primary Peritoneal Cancer AJCC v8;   Stage IIIA1 Fallopian Tube Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Fallopian Tube Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Fallopian Tube Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Primary Peritoneal Cancer AJCC v8;   Stage IIIC Fallopian Tube Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Primary Peritoneal Cancer AJCC v8;   Stage IV Fallopian Tube Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Primary Peritoneal Cancer AJCC v8;   Stage IVA Fallopian Tube Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Primary Peritoneal Cancer AJCC v8;   Stage IVB Fallopian Tube Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Primary Peritoneal Cancer AJCC v8
    Intervention:   Biological: PRGN-3005 UltraCAR-T cells
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Precigen, Inc
    Recruiting
  • Management of Pleural Space Infections
    NCT03873766
    Conditions:   Empyema, Pleural;   Parapneumonic Effusion
    Interventions:   Drug: Intrapleural Medications;   Procedure: Surgery;   Procedure: Pleural Sampling;   Procedure: Pleural fluid drainage;   Radiation: Protocol Image #1;   Other: Surgical Consultation;   Radiation: Protocol Image #2: Chest X-ray PA/Lateral;   Behavioral: Quality of Life
    Sponsor:   Swedish Medical Center
    Recruiting
  • TAP Blocks vs. IV Lidocaine for Kidney Transplants
    NCT03843879
    Condition:   Postoperative Pain
    Interventions:   Procedure: Transversus Abdominis Plane Block;   Drug: Intravenous Lidocaine
    Sponsor:   Benaroya Research Institute
    Recruiting
  • Poststroke Depression in Hemorrhagic Stroke
    NCT03826875
    Conditions:   Stroke Hemorrhagic;   Depression
    Interventions:   Drug: Fluoxetine;   Drug: Placebo
    Sponsor:   University of Washington
    Recruiting
  • MBCT and CBT for Chronic Pain in Multiple Sclerosis
    NCT03782246
    Condition:   Multiple Sclerosis
    Interventions:   Behavioral: MBCT;   Behavioral: CBT
    Sponsors:   University of Washington;   National Multiple Sclerosis Society
    Recruiting
  • Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors
    NCT03781778
    Conditions:   Colon Cancer;   Rectal Cancer;   Cancer Survivor;   Colorectal Adenocarcinoma;   Stage I Colorectal Cancer AJCC v8;   Stage II Colorectal Cancer AJCC v8;   Stage IIA Colorectal Cancer AJCC v8;   Stage IIB Colorectal Cancer AJCC v8;   Stage IIC Colorectal Cancer AJCC v8;   Stage III Colorectal Cancer AJCC v8;   Stage IIIA Colorectal Cancer AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8
    Interventions:   Other: Dietary Intervention (resistant starch);   Other: Dietary Intervention (regular starch);   Other: Questionnaire Administration
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Acute Exercise Intervention in Reducing Breast Cancer Risk in Healthy Participants
    NCT03779867
    Conditions:   Healthy Subject;   Breast Cancer Female
    Interventions:   Behavioral: Exercise Intervention;   Other: Resting;   Other: Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
    NCT03776864
    Condition:   Hodgkin's Lymphoma
    Interventions:   Biological: Pembrolizumab;   Drug: Umbralisib
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
    NCT03747484
    Condition:   Other Skin
    Interventions:   Biological: Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR;   Drug: Avelumab;   Radiation: Radiation Therapy;   Biological: Pembrolizumab
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Bluebird Biosciences
    Recruiting
  • Strategies to Improve Pain and Enjoy Life
    NCT03743402
    Condition:   Chronic Pain
    Interventions:   Behavioral: Pain self-management training;   Behavioral: video education, motivational interviewing;   Drug: voluntary self-paced opioid taper;   Drug: prescribing guidance for primary care provider;   Other: usual care
    Sponsors:   University of Washington;   Kaiser Permanente
    Recruiting
  • Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy
    NCT03723863
    Conditions:   Breast Cancer Stage I;   Breast Cancer Stage III;   Breast Cancer Stage II;   Breast Cancer Stage IIA;   Breast Cancer Stage IIB;   Breast Cancer Stage IIIA;   Breast Cancer Stage IIIB;   Breast Cancer Stage IIIc;   Breast Cancer
    Intervention:   Behavioral: Occupational Therapy
    Sponsor:   University of Washington
    Recruiting
  • Back on Track to Healthy Living Study
    NCT03687762
    Condition:   Chronic Pain
    Interventions:   Behavioral: Cognitive Therapy (CT);   Behavioral: Mindfulness Meditation (MM);   Behavioral: Activation Skills (AS)
    Sponsors:   University of Washington;   Rush University;   Medical University of South Carolina;   The University of Queensland;   National Center for Complementary and Integrative Health (NCCIH)
    Recruiting
  • 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome
    NCT03670966
    Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   CD45-Positive Neoplastic Cells Present;   Chronic Myelomonocytic Leukemia;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Myeloproliferative Neoplasm;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Biological: Granulocyte Colony-Stimulating Factor
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Itacitinib in Treating Patients With Refractory Metastatic/Advanced Soft Soft Tissue Sarcomas
    NCT03670069
    Conditions:   Metastatic Leiomyosarcoma;   Metastatic Synovial Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Advanced Myxoid Liposarcoma;   Advanced Soft Tissue Sarcoma;   Metastatic Myxoid Liposarcoma;   Metastatic Round Cell Liposarcoma;   Metastatic Soft Tissue Sarcoma;   Refractory Leiomyosarcoma;   Refractory Myxoid Liposarcoma;   Refractory Round Cell Liposarcoma;   Refractory Soft Tissue Sarcoma;   Refractory Synovial Sarcoma;   Refractory Undifferentiated Pleomorphic Sarcoma
    Interventions:   Drug: Itacitinib;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Incyte Corporation;   National Cancer Institute (NCI)
    Recruiting
  • The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors
    NCT03641287
    Conditions:   Ovarian Cancer;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Carcinosarcoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Malignant Ovarian Brenner Tumor;   Ovarian Adenocarcinoma;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Primary Peritoneal Carcinosarcoma;   Primary Peritoneal Transitional Cell Carcinoma
    Interventions:   Other: Exercise Counseling;   Other: Aerobic Exercise;   Other: Physiological Support;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Best Practice
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Genetic Influences on Response to Gait Rehabilitation in Parkinson's Disease
    NCT03607695
    Condition:   Parkinson's Disease
    Intervention:   Other: Gait training
    Sponsors:   VA Office of Research and Development;   University of Washington
    Recruiting
  • Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer
    NCT03606486
    Conditions:   High Grade Ovarian Serous Adenocarcinoma;   Stage III Ovarian Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8
    Interventions:   Other: Biospecimen Collection;   Other: Laboratory Biomarker Analysis;   Other: Lavage;   Other: Pap Smear
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   Minnesota Ovarian Cancer Alliance
    Recruiting
  • Enhanced E-cigarette Coaching Intervention for Dual Users of Cigarettes and E-cigarettes
    NCT03575468
    Condition:   Smoking Cessation
    Interventions:   Behavioral: Enhanced E-cigarette Coaching;   Behavioral: Quitline treatment as usual
    Sponsors:   Alere Wellbeing;   University of Oklahoma;   SRI International;   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting
  • Hypnosis and Meditation for Cancer Pain
    NCT03558594
    Conditions:   Pain Related to Cancer;   Cancer of Head and Neck
    Interventions:   Behavioral: Hypnosis;   Behavioral: Mindfulness
    Sponsor:   VA Puget Sound Health Care System
    Recruiting
  • Auto Control of Volume Management for Limb Loss
    NCT03550118
    Condition:   Lower Limb Amputation Below Knee (Injury)
    Intervention:   Device: Adjustable socket
    Sponsor:   University of Washington
    Recruiting
  • Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests
    NCT03539614
    Condition:   Posttraumatic Stress Disorder
    Interventions:   Drug: Prazosin;   Drug: Placebo
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Pivot-Flex Foot: Optimal Coupling Ratio Between Transverse and Sagittal-plane Motions Using a Torsionally Adaptive Prosthesis for Individuals With Lower Limb Amputation
    NCT03532100
    Condition:   Lower Extremity Amputation
    Interventions:   Device: Torsionally adaptive prosthesis with 0:1 coupling ratio;   Device: Torsionally adaptive prosthesis with 1:6 coupling ratio;   Device: Torsionally adaptive prosthesis with 1:4 coupling ratio;   Device: Torsionally adaptive prosthesis with 1:3 coupling ratio;   Device: Torsionally adaptive prosthesis with 1:2 coupling ratio
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm
    NCT03531918
    Conditions:   Acute Myeloid Leukemia;   High-Grade Myeloid Neoplasm;   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Blasts 10 Percent or More of Peripheral Blood White Cells;   High Grade Myeloid Neoplasm
    Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Drug: Gemtuzumab Ozogamicin;   Biological: Granulocyte Colony-Stimulating Factor;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Pfizer
    Recruiting
  • Do Rocker Bottom Shoes and Ankle-Foot Orthoses Reduce Pain and Improve Mobility for Ankle Osteoarthritis Patients
    NCT03524729
    Conditions:   Ankle Osteoarthritis;   Healthy Ankles
    Interventions:   Device: Rocker bottom shoe;   Device: Ankle foot orthosis;   Device: Standard walking shoe
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    NCT03522584
    Conditions:   Metastatic Head and Neck Squamous Cell Carcinoma;   Recurrent Head and Neck Squamous Cell Carcinoma
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Radiation: Stereotactic Body Radiation Therapy;   Biological: Tremelimumab;   Procedure: Hypofractionated Image-Guided Radiation Therapy
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Selecting Effective Combinations of Treatment for Low Back Pain
    NCT03520387
    Condition:   Low Back Pain
    Interventions:   Procedure: Lumbar medial branch nerve radiofrequency ablation (LRFA);   Procedure: Simulated LRFA with targeted steroid injections;   Behavioral: AcTIVE-CBT;   Behavioral: TBSCE
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Testosterone and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer
    NCT03516812
    Conditions:   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Prostate Adenocarcinoma;   PSA Level Greater Than or Equal to One;   PSA Progression
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Other: Survey Administration;   Drug: Testosterone Enanthate;   Drug: Testosterone Cypionate
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
    NCT03498612
    Conditions:   B-Cell Non-Hodgkin Lymphoma;   Follicular Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Marginal Zone Lymphoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
    NCT03442556
    Conditions:   ATM Gene Mutation;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Homologous Recombination Deficiency;   Prostate Carcinoma Metastatic in the Bone;   PSA Level Greater Than or Equal to Two;   PSA Progression;   Stage IV Prostate Adenocarcinoma AJCC v7
    Interventions:   Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Rucaparib Camsylate;   Drug: Rucaparib
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Improving the Detection, Classification and Treatment of Misaligned Arthritic Ankles
    NCT03440008
    Condition:   Ankle Osteoarthritis
    Interventions:   Other: Dynamic 3D bone motion capture;   Device: wedged insole
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Fluorescence QRH-882260 Peptide Imaging in the Bile Duct
    NCT03438435
    Condition:   Cholangiocarcinoma
    Intervention:   Drug: QRH-882260 Heptapeptide
    Sponsors:   D. Kim Turgeon, MD;   University of Washington
    Recruiting
  • Microprocessor Knees in Early Rehabilitation
    NCT03433300
    Condition:   Amputation
    Interventions:   Device: Ottobock Kenevo/C-Leg;   Device: Ottobock 3R60/3R62
    Sponsors:   University of Washington;   United States Department of Defense;   Otto Bock Healthcare Products GmbH
    Recruiting
  • Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
    NCT03401853
    Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Rituximab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
    NCT03338972
    Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Biological: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Juno Therapeutics, Inc.;   National Cancer Institute (NCI)
    Recruiting
  • Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
    NCT03331341
    Condition:   Classical Hodgkin Lymphoma
    Interventions:   Drug: Dacarbazine;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Drug: Vinblastine;   Drug: Doxorubicin
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   Merck Sharp & Dohme Corp.
    Recruiting
  • A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
    NCT03277729
    Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma;   Recurrent Transformed B-cell Non-Hodgkin Lymphoma;   Recurrent Transformed Chronic Lymphocytic Leukemia;   Refractory Marginal Zone Lymphoma;   Refractory Transformed B-cell Non-Hodgkin Lymphoma;   Refractory Transformed Chronic Lymphocytic Leukemia
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis;   Drug: Fludarabine Phosphate
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
    NCT03260504
    Conditions:   Clear Cell Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
    Interventions:   Biological: Aldesleukin;   Biological: Pembrolizumab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Prazosin and CSF Biomarkers in mTBI
    NCT03221751
    Condition:   Dementia
    Interventions:   Drug: prazosin hydrochloride;   Drug: placebo
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Bioimpedance as a Diagnostic Tool for Assessing the Need for Socket Modification in Transtibial Amputees
    NCT03164356
    Condition:   Transtibial Amputee
    Intervention:   Other: Socket Modification Regime
    Sponsor:   University of Washington
    Recruiting
  • 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
    NCT03128034
    Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   High Risk Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Excess Blasts;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Lymphoblastic Leukemia;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Mixed Phenotype Acute Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Mixed Phenotype Acute Leukemia
    Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Pretargeted Radioimmunotherapy;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Device: Fludarabine
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
    NCT03103971
    Conditions:   Adult B Acute Lymphoblastic Leukemia;   BCL2 Gene Rearrangement;   BCL6 Gene Rearrangement;   CD19 Positive;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   MYC Gene Rearrangement;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma
    Interventions:   Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis;   Other: Pharmacological Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
    NCT03074318
    Conditions:   Metastatic Leiomyosarcoma;   Metastatic Liposarcoma;   Unresectable Leiomyosarcoma;   Unresectable Liposarcoma
    Interventions:   Drug: Avelumab;   Drug: Trabectedin
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Groups for Regaining Our Wellbeing
    NCT03058952
    Conditions:   Gulf War;   Fatigue;   Pain;   Depression
    Interventions:   Behavioral: Mindfulness-Based Stress Reduction;   Behavioral: Chronic Disease Self-Management Program
    Sponsor:   VA Office of Research and Development
    Recruiting
  • HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions
    NCT03051516
    Conditions:   High Grade Anal Canal Squamous Intraepithelial Neoplasia;   Vulvar High Grade Squamous Intraepithelial Lesion
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Questionnaire Administration;   Biological: Recombinant Human Papillomavirus Nonavalent Vaccine
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
    NCT03023046
    Conditions:   Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Dasatinib;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
    NCT03012672
    Conditions:   Acute Leukemia of Ambiguous Lineage;   Acute Myeloid Leukemia;   Myeloid Neoplasm
    Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Biological: Granulocyte Colony-Stimulating Factor;   Drug: Mitoxantrone Hydrochloride;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Patient Fitness and Body Composition During Hematopoietic Stem Cell Transplantation
    NCT02990130
    Condition:   Hematologic Malignancy
    Intervention:   Other: Observational
    Sponsor:   Garcia, Jose M., MD, PhD
    Recruiting
  • Metabolic and QOL Effects of GH Treatment in Patients With TBI and AGHD
    NCT02988687
    Condition:   Adult-Onset Growth Hormone Deficiency
    Intervention:  
    Sponsor:   Garcia, Jose M., MD, PhD
    Recruiting
  • Strong Men, Strong Communities Diabetes Risk Reduction in American Indian Men
    NCT02953977
    Condition:   Diabetes
    Intervention:   Behavioral: Diabetes Prevention Program
    Sponsor:   Washington State University
    Recruiting
  • Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
    NCT02943668
    Conditions:   Anemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Deferasirox;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Novartis Pharmaceuticals
    Recruiting
  • Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
    NCT02756572
    Conditions:   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia-2;   High Grade Malignant Neoplasm;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2;   Myeloid Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Cladribine;   Drug: Cyclosporine;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mitoxantrone Hydrochloride;   Drug: Mycophenolate Mofetil;   Other: Questionnaire Administration;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Drug: Melphalan Hydrochloride
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
    NCT02706405
    Conditions:   BCL2 Gene Rearrangement;   BCL6 Gene Rearrangement;   CD19 Positive;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   MYC Gene Rearrangement;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
    Interventions:   Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014;   Drug: Cyclophosphamide;   Biological: Durvalumab;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   AstraZeneca;   Juno Therapeutics, Inc.;   MedImmune LLC;   National Cancer Institute (NCI)
    Recruiting
  • Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
    NCT02598895
    Conditions:   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma;   Prostate Carcinoma Metastatic in the Bone;   PSA Progression;   Stage IV Prostate Cancer
    Interventions:   Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
    NCT02565901
    Conditions:   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma;   Prostate Carcinoma Metastatic in the Bone;   PSA Level Greater Than or Equal to Two;   PSA Progression;   Stage IV Prostate Cancer AJCC v7
    Interventions:   Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Sirolimus
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer
    NCT02454517
    Conditions:   Obesity;   Overweight;   Prostate Adenocarcinoma;   Stage I Prostate Cancer AJCC V7;   Stage IIA Prostate Cancer AJCC v7
    Interventions:   Behavioral: Behavioral Dietary Intervention;   Behavioral: Exercise Intervention;   Other: Informational Intervention;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
    NCT02339922
    Conditions:   Chronic Lymphocytic Leukemia;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer
    NCT02334579
    Conditions:   Prostate Cancer;   Prostatic Cancer;   Prostate Neoplasms;   Prostatic Neoplasms;   Cancer of the Prostate
    Intervention:   Radiation: CyberKnife Stereotactic Radiosurgery
    Sponsor:   Swedish Medical Center
    Recruiting
  • Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin
    NCT02266329
    Conditions:   Posttraumatic Headache;   Combat Disorders;   Post Concussion Syndrome;   Headache;   Mild Traumatic Brain Injury;   Posttraumatic Migraine
    Interventions:   Drug: prazosin hydrochloride;   Drug: placebo
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
    NCT02227199
    Conditions:   Recurrent Adult Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   TNFRSF8 Positive
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Project to Improve Communication About Serious Illness - Pilot Study
    NCT03746392
    Conditions:   Malignant Neoplasm;   Leukemia, Lymphocytic, Chronic, B-Cell;   Lung Disease Chronic;   Congestive Heart Failure;   Liver Failures, Chronic;   Renal Insufficiency, Chronic;   Dementia;   Diabetes Complications;   Peripheral Vascular Disease;   Frail Elderly
    Intervention:   Behavioral: Jumpstart Intervention
    Sponsor:   University of Washington
    Recruiting
  • Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
    NCT02157051
    Conditions:   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage III Breast Cancer
    Interventions:   Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Washington;   United States Department of Defense;   National Cancer Institute (NCI)
    Recruiting
  • TBI Care: Collaborative Care for Pain After Traumatic Brain Injury (TBI)
    NCT03523923
    Conditions:   Brain Injuries, Traumatic;   Chronic Pain;   Post-Traumatic Headache
    Intervention:   Behavioral: Collaborative Care
    Sponsors:   University of Washington;   National Institute on Disability, Independent Living, and Rehabilitation Research
    Recruiting
  • Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
    NCT01703949
    Conditions:   CD30-Positive Neoplastic Cells Present;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
    NCT02881554
    Conditions:   Hepatocellular Carcinoma;   Intrahepatic Cholangiocarcinoma;   Stage IV Liver Cancer;   Stage IVA Liver Cancer;   Stage IVB Liver Cancer;   Vascular Thrombosis
    Interventions:   Procedure: Computed Tomography;   Procedure: Single Photon Emission Computed Tomography;   Drug: Technetium Tc-99m Sulfur Colloid
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
    NCT02773238
    Conditions:   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7;   Stage IIIB Non-Small Cell Lung Cancer AJCC v7
    Interventions:   Procedure: Computed Tomography;   Radiation: Fludeoxyglucose F-18;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography;   Radiation: Radiation Therapy;   Procedure: Single Photon Emission Computed Tomography;   Radiation: Technetium Tc-99m Albumin Aggregated;   Radiation: Technetium Tc-99m Sulfur Colloid
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Orthotic Dose Response Study
    NCT02629731
    Conditions:   Ankle Osteoarthritis;   Flat Foot or Pes Planus
    Intervention:   Device: custom orthoses with varying degrees of hindfoot posting
    Sponsors:   VA Office of Research and Development;   University of Washington
    Recruiting
  • Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
    NCT01050504
    Conditions:   Healthy Control;   Localized Urothelial Carcinoma of the Renal Pelvis and Ureter;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Recurrent Bladder Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage IV Bladder Cancer;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Prostate Cancer
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Individualizing Incentives for Alcohol in the Severely Mentally Ill
    NCT03481049
    Conditions:   Schizophrenia;   Bipolar Disorder;   Major Depressive Disorder;   Alcohol Dependence
    Interventions:   Behavioral: Usual CM;   Behavioral: High-Magnitude CM;   Behavioral: Shaping CM
    Sponsors:   Washington State University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    Recruiting
  • Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
    NCT04060849
    Conditions:   Viral Upper Respiratory Tract Infection;   Allogeneic Bone Marrow Transplantation Recipient
    Interventions:   Drug: Nozin;   Other: Best Practice
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Global Life Technologies Corp.
    Recruiting
  • In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days
    NCT04022889
    Condition:   Healthy
    Intervention:   Device: INTERCEPT Treated Platelets
    Sponsor:   Cerus Corporation
    Recruiting
  • CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
    NCT03933826
    Conditions:   Bladder Cancer;   Cancer of the Bladder, Recurrent;   Non-muscle Invasive Bladder Cancer
    Intervention:  
    Sponsors:   University of Washington;   Patient-Centered Outcomes Research Institute
    Recruiting
  • TR1801-ADC in Patients With Tumors That Express c-Met
    NCT03859752
    Condition:   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Biological: TR1801-ADC
    Sponsors:   Tanabe Research Laboratories USA Inc;   Open Innovation Partners
    Recruiting
  • Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue
    NCT03621761
    Condition:   Multiple Sclerosis
    Interventions:   Behavioral: Telephone-based Cognitive Behavioral Therapy;   Drug: Modafinil
    Sponsors:   University of Michigan;   University of Washington;   Patient-Centered Outcomes Research Institute;   National Multiple Sclerosis Society
    Recruiting
  • Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM
    NCT03608774
    Condition:   Anal Chlamydia Infection
    Interventions:   Drug: Azithromycin;   Drug: Doxycycline;   Other: Placebo
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting
  • Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
    NCT03599362
    Condition:   Pancreatic Cancer
    Interventions:   Drug: Nivolumab + Cabiralizumab;   Radiation: Stereotactic Body Radiotherapy (SBRT)
    Sponsor:   NYU Langone Health
    Recruiting
  • Alcohol Research Consortium in HIV-Intervention Research Arm
    NCT02938377
    Conditions:   HIV Positive;   Alcohol Use
    Interventions:   Behavioral: Computerized Brief Intervention (CBI);   Behavioral: CBT4CBT;   Drug: Recommendation and Counseling for Alcohol Pharmacotherapy
    Sponsor:   University of Alabama at Birmingham
    Recruiting
  • ESTIA: Computerized Intervention Targeting Cognitive Control Deficits in Depressed Adults
    NCT02891564
    Condition:   Major Depression
    Interventions:   Behavioral: Band Together;   Other: Control Mobile 3D video game
    Sponsors:   University of Washington;   Weill Medical College of Cornell University;   University of California, San Francisco
    Recruiting
  • Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
    NCT02721979
    Conditions:   Prostate Adenocarcinoma;   Testosterone Greater Than or Equal to 150 ng/dL
    Interventions:   Drug: Apalutamide;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   University of Washington;   Janssen Scientific Affairs, LLC;   National Cancer Institute (NCI)
    Recruiting
  • Advancing Symptom Alleviation With Palliative Treatment
    NCT02713347
    Conditions:   Heart Failure;   Pulmonary Disease, Chronic Obstructive;   Emphysema;   Pulmonary Fibrosis, Interstitial Lung Disease
    Intervention:   Behavioral: ADAPT Intervention
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
    NCT02451553
    Conditions:   Advanced Malignant Solid Neoplasm;   Bile Duct Carcinoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Pancreatic Carcinoma;   Stage III Pancreatic Cancer AJCC v6 and v7;   Stage IVA Pancreatic Cancer;   Stage IVB Pancreatic Cancer
    Interventions:   Drug: Afatinib Dimaleate;   Drug: Capecitabine;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Facilitating Communication Study
    NCT03721952
    Conditions:   Chronic Disease;   Neoplasm Metastasis;   Lung Neoplasm;   Pulmonary Disease, Chronic Obstructive;   Heart Failure, Congestive;   Liver Cirrhosis;   Kidney Failure, Chronic;   Multiple Organ Failure;   Health Care Quality, Access, and Evaluation;   Intensive Care Units;   Palliative Care, Health Services;   Palliative Care, Patient Care;   Lung Diseases, Interstitial
    Intervention:   Behavioral: Facilitator-Based Intervention
    Sponsor:   University of Washington
    Recruiting
  • Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
    NCT03864419
    Conditions:   Burkitt Lymphoma;   KSHV-associated Multicentric Castleman Disease;   Diffuse Large B-Cell Lymphoma
    Interventions:   Biological: Rituximab or Rituximab Hyaluronidase Human;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Drug: Etoposide
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Yeego! Healthy Eating & Gardening
    NCT03778021
    Conditions:   Dietary Habits;   Health Behavior;   Eating Behavior
    Interventions:   Behavioral: Behavioral Gardening Exposure;   Behavioral: Healthy Eating and Gardening Curriculum;   Behavioral: Family Workshops
    Sponsor:   Fred Hutchinson Cancer Research Center
    Recruiting
  • Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Participants With Acute Myeloid Leukemia
    NCT03737955
    Conditions:   Acute Myeloid Leukemia;   CD33 Positive;   Minimal Residual Disease
    Interventions:   Drug: Gemtuzumab Ozogamicin;   Other: Quality-of-Life Assessment
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Understanding Prosthetic Needs and Outcomes in Women Veterans With Amputation
    NCT03733054
    Condition:   Amputation
    Intervention:  
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Prostate Adenocarcinoma
    NCT03718338
    Condition:   Prostate Adenocarcinoma
    Interventions:   Procedure: Evaluation;   Other: Quality-of-Life Assessment
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease
    NCT03483675
    Conditions:   Chronic Graft Versus Host Disease;   Hematopoietic Cell Transplantation Recipient
    Interventions:   Biological: Immunosuppressive Therapy;   Other: Survey Administration
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
    NCT03246906
    Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Hematopoietic Cell Transplant Recipient;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Veteran Peer Coaches Optimizing and Advancing Cardiac Health
    NCT02697422
    Conditions:   Cardiovascular Disease (CVD);   Hypertension;   Hyperlipemia;   Obesity
    Intervention:   Other: Community-based peer health coach intervention
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
    NCT01028716
    Conditions:   Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma;   Hematopoietic Cell Transplant Recipient
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Fludarabine
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • The GBA Multimodal Study in Parkinson's Disease
    NCT04101968
    Conditions:   Parkinson Disease;   GBA Gene Mutation;   Gaucher Disease
    Interventions:   Diagnostic Test: PET scan;   Diagnostic Test: neuroQWERTY
    Sponsors:   Pacific Parkinson's Research Centre;   University of British Columbia;   University of Washington;   Oregon Health and Science University;   Simon Fraser University;   Michael J. Fox Foundation for Parkinson's Research;   Silverstein Foundation;   Weston Brain Institute
    Recruiting
  • Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study
    NCT03811171
    Conditions:   Renal Calculi;   Urinary Calculi
    Intervention:   Device: Break Wave extracorporeal lithotripsy
    Sponsor:   SonoMotion
    Recruiting
  • Diet Intervention for Hypertension: Adaptation and Dissemination to Native Communities
    NCT02796313
    Condition:   Hypertension
    Interventions:   Behavioral: DASH Groceries + Weekly Sessions;   Behavioral: Groceries + Brochure
    Sponsors:   Washington State University;   Oklahoma State University
    Recruiting
  • Glasdegib for Chronic Graft-Versus-Host Disease
    NCT04111497
    Conditions:   Chronic Graft Versus Host Disease;   Fasciitis;   Sclerosis
    Intervention:   Drug: Glasdegib
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Pfizer
    Recruiting
  • Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors
    NCT04064294
    Conditions:   Parkinson Disease;   Dyskinesia, Drug-Induced
    Intervention:   Drug: Intravenous Infusion
    Sponsors:   VA Office of Research and Development;   Oregon Health and Science University
    Recruiting
  • Optimizing a Mobile Mindfulness Intervention for ICU Survivors
    NCT04038567
    Condition:   Cardiorespiratory Failure
    Intervention:   Behavioral: Mobile mindfulness-based training
    Sponsors:   Duke University;   University of Washington;   University of Colorado, Denver;   National Center for Complementary and Integrative Health (NCCIH)
    Recruiting
  • A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors
    NCT03934359
    Condition:   Advanced Solid Tumors
    Intervention:   Drug: DN1508052-01
    Sponsor:   Shanghai De Novo Pharmatech Co., Ltd.
    Recruiting
  • Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
    NCT03796884
    Condition:   Colorectal Adenoma
    Interventions:   Drug: Linaclotide;   Other: Placebo
    Sponsors:   Sidney Kimmel Cancer Center at Thomas Jefferson University;   United States Department of Defense
    Recruiting
  • A Test-Drive Strategy for the Prescription of Prosthetic Feet for People With Leg Amputations
    NCT03651830
    Condition:   Amputation
    Interventions:   Device: Prosthetic Foot Emulator;   Device: Commercially available prosthetic feet
    Sponsors:   Seattle Institute for Biomedical and Clinical Research;   VA Puget Sound Health Care System;   Minneapolis Veterans Affairs Medical Center;   Brooke Army Medical Center;   Stanford University;   University of Washington
    Recruiting
  • Inpatient Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation
    NCT03641378
    Condition:   Stem Cell Transplant
    Interventions:   Other: Palliative Care Intervention;   Other: Standard Transplant Care
    Sponsors:   Massachusetts General Hospital;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting
  • Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment
    NCT03612804
    Conditions:   Smoking Reduction;   Tobacco Use;   Tobacco Smoking;   Tomography;   Lung Diseases;   Lung Neoplasms
    Interventions:   Behavioral: Unsigned note to provider about cessation medication prescription;   Behavioral: Proactive Telephone Counseling from VA Quitline
    Sponsors:   VA Office of Research and Development;   Fred Hutchinson Cancer Research Center
    Recruiting
  • Spinal Manipulation and Patient Self-Management for Preventing Acute to Chronic Back Pain
    NCT03581123
    Conditions:   Acute Pain;   Low Back Pain, Mechanical
    Interventions:   Behavioral: Supported-Self Management (SSM);   Other: Spinal Manipulation Therapy (SMT);   Combination Product: SMT + SSM;   Drug: Standard Medical Care (SMC)
    Sponsors:   University of Minnesota;   University of Pittsburgh;   University of Washington;   University of North Texas Health Science Center;   Oregon Health and Science University;   Duke University
    Recruiting
  • CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
    NCT03572764
    Condition:   Myelodysplastic Syndromes
    Interventions:   Drug: CPX-351;   Procedure: Research skin biopsy;   Procedure: Research blood draw;   Procedure: Research bone marrow aspirate
    Sponsors:   Washington University School of Medicine;   Jazz Pharmaceuticals
    Recruiting
  • Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
    NCT03099564
    Condition:   Hepatocellular Carcinoma
    Interventions:   Drug: Pembrolizumab;   Device: Y90 radioembolization
    Sponsors:   Autumn McRee, MD;   Merck Sharp & Dohme Corp.;   Hoosier Cancer Research Network
    Recruiting
  • Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma
    NCT03056599
    Condition:   Soft Tissue Sarcoma Adult
    Interventions:   Drug: Multiple drug microinjection;   Device: CIVO device
    Sponsors:   Presage Biosciences;   Fred Hutchinson Cancer Research Center;   University of Washington;   Northwell Health;   Oregon Health and Science University
    Recruiting
  • Alpers Huttenlocher Natural History Study
    NCT03034512
    Condition:   Alpers Huttenlocher Syndrome
    Intervention:  
    Sponsors:   Columbia University;   Seattle Children's Hospital;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting
  • Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
    NCT02985021
    Conditions:   Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
    Interventions:   Drug: Carboplatin;   Drug: Docetaxel
    Sponsors:   Seattle Institute for Biomedical and Clinical Research;   Prostate Cancer Foundation;   VA Puget Sound Health Care System
    Recruiting
  • Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
    NCT02535286
    Conditions:   Chronic Lymphocytic Leukemia;   Richter Syndrome
    Interventions:   Drug: Umbralisib;   Biological: ublituximab;   Biological: TG-1501
    Sponsors:   TG Therapeutics, Inc.;   Memorial Sloan Kettering Cancer Center
    Recruiting
  • Trial Comparing Relapse Rates Between Standard Ureteroscopic Removal Of Ureteral Stone And Standard Removal With Additional Ureterorenic Clearing Of Non-Symptomatic Stones In The Kidney
    NCT02210650
    Condition:   Ureteral Stones
    Interventions:   Procedure: Ureteral stone removal;   Procedure: Asymptomatic kidney stones and ureteral stone removed
    Sponsors:   Indiana Kidney Stone Institute;   University of Washington Medical Center Department of Urology (Seattle, WA);   VA Puget Sound Health Care System
    Recruiting
  • Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
    NCT01812252
    Conditions:   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Azacitidine;   Drug: Decitabine;   Other: Quality-of-Life Assessment
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases
    NCT00716066
    Conditions:   Autoimmune Disease;   Neurologic Autoimmune Disease;   Autologous Transplant Autoimmune;   Multiple Sclerosis Transplant;   MS Stem Cell Transplant;   Multiple Sclerosis Stem Cell Transplant;   Stiff Person Syndrome;   HCT for Neurologic Autoimmune Disorders;   CIDP Transplant;   Myasthenia Gravis Transplant
    Interventions:   Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Prednisone;   Procedure: Syngeneic Bone Marrow Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • Communication During Hospitalization About Resuscitation Trial
    NCT02984124
    Conditions:   Severe Life-limiting COPD;   Severe Life-limiting Heart Failure;   Severe Life-limiting Cirrhosis;   Severe Life-limiting Malignancy;   Severe Functional Impairment
    Interventions:   Behavioral: Informed Assent Discussion;   Behavioral: Usual Care with Attention Control
    Sponsors:   University of Vermont;   University of Washington;   Medical University of South Carolina;   University of California, San Francisco
    Recruiting
  • A Phase 1 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD
    NCT03604692
    Condition:   Chronic Graft-versus-host-disease
    Intervention:   Drug: SNDX-6352
    Sponsor:   Syndax Pharmaceuticals
    Recruiting
  • Neurocognition in Congenital Central Hypoventilation Syndrome (CCHS)
    NCT03568669
    Conditions:   Congenital Central Hypoventilation Syndrome;   Congenital Central Hypoventilation;   CCHS;   CCHS With Hirschsprung Disease;   CCHS With Neural Crest Tumor;   CCHS With Neuroblastoma
    Intervention:   Other: NIH Toolbox Cognition Battery
    Sponsors:   Debra Weese-Mayer;   Ann & Robert H Lurie Children's Hospital of Chicago;   Seattle Children's Hospital;   Children's Hospital Los Angeles
    Recruiting
  • Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)
    NCT02684422
    Conditions:   Methicillin-Resistant Staphylococcus Aureus;   Cystic Fibrosis
    Intervention:   Other: Intervention N/A. Observational study
    Sponsor:   University of North Carolina, Chapel Hill
    Recruiting
  • A Pilot Study of Oraxol in Subjects With Cutaneous Angiosarcoma
    NCT03544567
    Condition:   Angiosarcoma of Skin
    Intervention:   Drug: Oraxol
    Sponsor:   Athenex, Inc.
    Recruiting
  • HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
    NCT02143830
    Conditions:   Fanconi Anemia;   Severe Marrow Failure;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: rabbit ATG;   Drug: G-CSF;   Biological: Peripheral blood stem cell
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   Memorial Sloan Kettering Cancer Center;   Fred Hutchinson Cancer Research Center
    Recruiting
  • Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
    NCT03616184
    Condition:   Graft-versus-host-disease (GVHD)
    Intervention:   Drug: Ruxolitinib
    Sponsor:   University of Nebraska
    Recruiting
  • A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
    NCT03582033
    Condition:   Multiple Myeloma
    Intervention:   Drug: SEA-BCMA
    Sponsor:   Seattle Genetics, Inc.
    Recruiting
  • A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)
    NCT03215030
    Condition:   Multiple Myeloma
    Interventions:   Drug: TAK-573;   Drug: Dexamethasone
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting
  • High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
    NCT03179761
    Condition:   Hematopoietic Cell Transplantation
    Interventions:   Biological: Quadrivalent Inactivated Influenza Vaccine;   Other: Laboratory Biomarker Analysis;   Biological: Trivalent Influenza Vaccine
    Sponsor:   Vanderbilt-Ingram Cancer Center
    Recruiting
  • Opioid Use Disorder in the Emergency Department: CTN 0069
    NCT03023930
    Condition:   Opioid Use Disorder
    Interventions:   Other: Standard Dissemination Practice;   Other: Implementation Facilitation (IF)
    Sponsors:   Yale University;   National Institute on Drug Abuse (NIDA);   The Emmes Company, LLC
    Recruiting
  • Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma
    NCT03016871
    Conditions:   Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Refractory Metastatic Anal Cancer
    NCT02919969
    Condition:   Anal Cancer
    Intervention:   Drug: Pembrolizumab
    Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
    Recruiting
  • Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
    NCT03737981
    Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Observation;   Drug: Venetoclax
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
    NCT03633331
    Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2/Neu Negative;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
    NCT02972840
    Condition:   Lymphoma, Mantle Cell
    Interventions:   Drug: Acalabrutinib in combination with bendamustine and rituximab;   Drug: Placebo in combination with bendamustine and rituximab
    Sponsor:   Acerta Pharma BV
    Recruiting
  • Diffusion MRI-1 Imaging Database
    NCT03775694
    Conditions:   Epilepsy;   Tumor;   Healthy;   Other
    Intervention:   Device: dMRI Scan
    Sponsor:   Medtronic Surgical Technologies
    Recruiting
  • Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
    NCT04131036
    Condition:   Hemophilia A
    Intervention:   Other: assessment of joint health and bone density
    Sponsors:   Bloodworks;   Genentech, Inc.
    Recruiting
  • Dried Blood Spot Testing of CMV Detection in HCT Recipients
    NCT03910478
    Condition:   Cytomegalovirus Infection
    Interventions:   Device: DBS Self-Collection Kit;   Other: Standard Control Strategy
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting
  • Brain Oxygen Optimization in Severe TBI, Phase 3
    NCT03754114
    Condition:   Brain Injuries, Traumatic
    Interventions:   Other: ICP + PbtO2 guided management strategy;   Other: ICP guided management strategy
    Sponsors:   University of Michigan;   National Institute of Neurological Disorders and Stroke (NINDS);   University of Washington;   University of Pennsylvania;   University of Pittsburgh;   Medical University of South Carolina
    Recruiting
  • Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
    NCT02437851
    Conditions:   Anal Squamous Cell Carcinoma;   HIV Infection;   Stage 0 Anal Canal Cancer;   Stage I Anal Canal Cancer
    Intervention:   Procedure: Therapeutic Conventional Surgery
    Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   The Emmes Company, LLC;   AIDS and Cancer Specimen Resource;   University of Arkansas
    Recruiting
  • Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
    NCT03157830
    Condition:   Relapsing Remitting Multiple Sclerosis
    Intervention:  
    Sponsors:   Providence Health & Services;   Genentech, Inc.
    Recruiting
  • RESPOND TO PREVENT: Stepwise Pharmacy Naloxone Study
    NCT03545321
    Conditions:   Pharmacies;   Opioid Use;   Patient Safety
    Intervention:   Behavioral: MOON+
    Sponsors:   Boston Medical Center;   Comagine Health;   Oregon Health and Science University;   University of Rhode Island;   University of Washington;   National Institute on Drug Abuse (NIDA)
    Recruiting
  • SEL24/MEN1703 in Patients With Acute Myeloid Leukemia
    NCT03008187
    Condition:   Acute Myeloid Leukemia
    Intervention:   Drug: SEL24/MEN1703
    Sponsors:   Menarini Group;   Medpace, Inc.;   Theradex
    Recruiting
  • Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer
    NCT02833883
    Conditions:   Prostate Cancer;   Castration Resistant Prostate Cancer
    Interventions:   Drug: Enzalutamide;   Drug: CC-115
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Celgene Corporation
    Recruiting
  • Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma
    NCT02823327
    Condition:   AIDS-Related Primary Effusion Lymphoma
    Interventions:   Genetic: Laboratory Biomarker Analysis;   Other: Medical Chart Review
    Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   University of California, San Diego;   University of Arkansas
    Recruiting
  • Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
    NCT02396134
    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Hodgkin Lymphoma;   Adult Non-Hodgkin Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegaloviral Infection;   Hematopoietic and Lymphoid Cell Neoplasm;   HLA-A*0201 Positive Cells Present;   Myelodysplastic Syndrome;   Adult Lymphoblastic Lymphoma;   Chronic Lymphocytic Leukemia;   Myelofibrosis;   Myeloproliferative Neoplasm
    Interventions:   Biological: CMVpp65-A*0201 peptide vaccine;   Other: Placebo;   Other: Laboratory Biomarker Analysis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting
  • Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer
    NCT04095364
    Conditions:   Low Grade Ovarian Serous Adenocarcinoma;   Primary Peritoneal Low Grade Serous Adenocarcinoma;   Stage II Ovarian Cancer AJCC v8;   Stage IIA Ovarian Cancer AJCC v8;   Stage IIB Ovarian Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Drug: Letrozole;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
    NCT03937635
    Condition:   Smoldering Plasma Cell Myeloma
    Interventions:   Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting
  • Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
    NCT03701282
    Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
    NCT03694002
    Conditions:   Locally Advanced Thymic Carcinoma;   Metastatic Thymic Carcinoma;   Recurrent Thymic Carcinoma;   Unresectable Thymic Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Ramucirumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
    NCT03654768
    Condition:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Drug: Ruxolitinib Phosphate
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
    NCT03418961
    Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
    NCT03244384
    Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
    NCT03233711
    Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Other: Patient Observation
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
    NCT02912559
    Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
    NCT03971474
    Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
    NCT03033576
    Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
    NCT03793179
    Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
    NCT03768414
    Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
    Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
    NCT02465060
    Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
    NCT03723928
    Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
    Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
    NCT03698019
    Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
    Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
    NCT02443077
    Conditions:   Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
    Interventions:   Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacogenomic Study;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    NCT02502266
    Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Questionnaire Administration;   Drug: Topotecan;   Drug: Topotecan Hydrochloride
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
    NCT03499808
    Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
    Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
    NCT03414970
    Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
    Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
    NCT02224781
    Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
    NCT03148795
    Condition:   Prostate Cancer
    Intervention:   Drug: Talazoparib
    Sponsors:   Pfizer;   Medivation, Inc.
    Recruiting
  • Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
    NCT03087708
    Conditions:   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
    Interventions:   Drug: Naloxegol;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
    NCT02954874
    Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • S0820, Adenoma and Second Primary Prevention Trial
    NCT01349881
    Condition:   Colorectal Neoplasms
    Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
    Recruiting
  • Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
    NCT04094688
    Condition:   Colorectal Adenocarcinoma
    Interventions:   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Drug: Irinotecan;   Dietary Supplement: Cholecalciferol;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
    NCT04001829
    Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Invasive Breast Carcinoma;   Prognostic Stage I Breast Cancer AJCC v8;   Prognostic Stage IA Breast Cancer AJCC v8;   Prognostic Stage IB Breast Cancer AJCC v8;   Prognostic Stage II Breast Cancer AJCC v8;   Prognostic Stage IIA Breast Cancer AJCC v8;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8
    Interventions:   Drug: Docetaxel;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting
  • Genetic Testing in Guiding Treatment for Patients With Brain Metastases
    NCT03994796
    Conditions:   CDK Gene Mutation;   Metastatic Malignant Neoplasm in the Brain;   Metastatic Malignant Solid Neoplasm;   NTRK Family Gene Mutation;   PI3K Gene Mutation;   ROS1 Gene Mutation
    Interventions:   Drug: Abemaciclib;   Drug: PI3K Inhibitor GDC-0084;   Drug: Entrectinib
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Genentech, Inc.
    Recruiting
  • Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
    NCT03984448
    Conditions:   Diffuse Large B-Cell Lymphoma;   Double-Expressor Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Prednisone;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
    NCT03944941
    Conditions:   Skin Squamous Cell Carcinoma;   Metastatic Skin Cancer
    Interventions:   Drug: Avelumab;   Drug: Cetuximab
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
    NCT02004275
    Condition:   Multiple Myeloma in Relapse
    Interventions:   Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Celgene Corporation;   Millennium Pharmaceuticals, Inc.
    Recruiting
  • Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
    NCT03866382
    Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer
    NCT03811015
    Conditions:   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
    Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Patient Observation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
    NCT03793166
    Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
    NCT03712605
    Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
    Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
    NCT01896999
    Conditions:   Recurrent Classic Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
    NCT03439254
    Conditions:   Compensated Cirrhosis;   Nonalcoholic Steatohepatitis
    Interventions:   Drug: Obeticholic acid (10 mg);   Drug: Obeticholic acid (10 mg to 25 mg);   Drug: Placebo
    Sponsor:   Intercept Pharmaceuticals
    Recruiting
  • AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH
    NCT03028740
    Condition:   Nonalcoholic Steatohepatitis
    Interventions:   Drug: Cenicriviroc;   Drug: Placebo
    Sponsor:   Tobira Therapeutics, Inc.
    Recruiting
  • The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial
    NCT02800785
    Condition:   Appendicitis
    Interventions:   Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin;   Procedure: Appendectomy
    Sponsors:   University of Washington;   Patient-Centered Outcomes Research Institute
    Recruiting
  • Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
    NCT02761057
    Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC